SynthesisJournal of cancer research and clinical oncology2012
Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials.
Synthesis in Journal of cancer research and clinical oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Intravenous iron and iron deficiency anemia in patients with gastrointestinal cancer: A systematic review.PloS one · 2024Pooled it
- The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents.The Cochrane database of systematic reviews · 2016Pooled it
- Randomized trial of sucrosomial iron supplementation in patients with chemotherapy-related anemia treated with ESA.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Trial
- Trial
- Article
- Randomised Controlled Trial Evaluating the Impact of Intravenous Iron (ferric carboxymaltose) Supplementation Among Epithelial Ovarian Cancer Patients with Anemia.Indian journal of surgical oncology · 2025Article
- Decoding iron deficiency in cancer: mechanisms, immune modulation, and therapeutic potential.Frontiers in nutrition · 2025Review
- Absolute Iron Deficiency Anemia Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.Annals of surgical oncology · 2023Article
- Iron deficiency screening is a key issue in chronic inflammatory diseases: A call to action.Journal of internal medicine · 2022Review
- Ferric Carboxymaltose and Erythropoiesis-Stimulating Agent Treatment Reduces the Rate of Blood Transfusion in Refractory Anemia.Journal of clinical medicine · 2022Article
- Peri-operative blood management of Jehovah's Witnesses undergoing cytoreductive surgery for advanced ovarian cancer.Blood transfusion = Trasfusione del sangue · 2022Article
- Flipside of the Coin: Iron Deficiency and Colorectal Cancer.Frontiers in immunology · 2021Review
- Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update.Blood advances · 2019Review
- Anemia and Iron Deficiency in Cancer Patients: Role of Iron Replacement Therapy.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017Article
- Intravenous iron therapy for anemic cancer patients: a review of recently published clinical studies.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017Review
- Hemoglobin levels and quality of life in patients with symptomatic chemotherapy-induced anemia: the eAQUA study.Cancer management and research · 2016Article
- Iron metabolism and iron supplementation in cancer patients.Wiener klinische Wochenschrift · 2015Review
- Hematology: cast iron results for ESA use in cancer.Nature reviews. Clinical oncology · 2011Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIron supplementation could improve the hematopoietic response of erythropoiesis-stimulating agents (ESAs) used for chemotherapy-induced anemia.
methodsWe performed a meta-analysis of randomized, controlled trials by comparing parenteral or oral iron and no iron, when added to ESAs in anemic cancer patients, in order to calculate the relative risk (RR) of hematopoietic response and transfusions, the time required to reach this response, and toxicity.
resultsA total of 1,606 patients out of eight trials were available for meta-analysis. The RR of obtaining an hematopoietic response was 1.29 (P = 0.0001) with parenteral iron and 1.04 for oral iron (P = 0.59). The risk of transfusion was reduced with parenteral iron versus no iron (RR 0.77; P = 0.02) but not with oral iron (RR 0.68; P = 0.08). The time to reach hematopoietic response was 1 month shorter and no increased toxicity appeared with iron supplementation.
conclusionOverall parenteral iron reduces the risk of transfusions by 23% and increases the chance of hematopoietic response by 29% when compared with ESAs alone. On the contrary, oral iron does not increase hematopoietic response nor transfusion rate. The significance of these results is that the proportion of non-responders to ESAs will have strongly improved and quality of life and cost ameliorated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.